Dr. Emmanuelle Charpentier
ERS co-founder, patent co-owner, and 2020 Nobel Prize winner
The essential intellectual property for the practice of CRISPR/Cas9
Consisting of over 50 granted patents in over 80 countries, our portfolio represents the most foundational collection of CRISPR/Cas9 patents worldwide.
Empowering the CRISPR/Cas9 platform globally
Non-exclusive licenses are available to companies for internal research and sale of products and services, in a wide range of fields.